Home » Results From Phase III Study of Ivacaftor Monotherapy Showed Statistically Significant Improvements in Lung Function in People With Non-G551D Gating Mutations
Results From Phase III Study of Ivacaftor Monotherapy Showed Statistically Significant Improvements in Lung Function in People With Non-G551D Gating Mutations
Vertex announced positive results from its Phase III trial of Kalydeco (ivacaftor) in cystic fibrosis patients ages 6 and older who possess at least one gating mutation other than G551D.
The Wall Street Journal
The Wall Street Journal
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May